Literature DB >> 15238094

In vivo measurement of 5-aminolaevulinic acid-induced protoporphyrin IX photobleaching: a comparison of red and blue light of various intensities.

Valerie Nadeau1, Martin O'Dwyer, Khaled Hamdan, Iain Tait, Miles Padgett.   

Abstract

BACKGROUND: In recent years, 5-aminolaevulinic acid (ALA) has become an increasingly popular photosensitizing drug for use in both photodynamic therapy (PDT) and photodetection (PD) of cancers. ALA metabolizes within tissue to form the photosensitizer protoporphyrin IX (PpIX). Like most photosensitizers, PpIX is fluorescent, and this fluorescence progressively decreases during PDT. This phenomenon is referred to as photobleaching. AIM: Our aim in carrying out this experiment was twofold: firstly, to compare the relative capacity of red and blue light to cause photobleaching; and secondly, to compare the capacity of a fixed light dose to cause photobleaching, when delivered at different intensities.
METHOD: In this paper, we describe the implementation of a compact fluorescence spectrometer in monitoring the photobleaching of ALA-induced PpIX in vivo on the skin of healthy volunteers.
RESULTS: We have been able to show that blue light causes more rapid photobleaching than red light, and that under illumination with red or blue light, delivery of a fixed light dose at a lower intensity results in more photobleaching.
CONCLUSION: Comparison of the photobleaching rates suggests that a blue light intensity of 5 mW/cm(2) gives the same rate of photobleaching as the typical red light PDT intensity of 100 mW/cm(2). Further investigation of the correlation between PpIX photobleaching and PDT effect would be beneficial in interpreting the clinical significance of our findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238094     DOI: 10.1111/j.1600-0781.2004.00100.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  6 in total

1.  Techniques for fluorescence detection of protoporphyrin IX in skin cancers associated with photodynamic therapy.

Authors:  Kishore R Rollakanti; Stephen C Kanick; Scott C Davis; Brian W Pogue; Edward V Maytin
Journal:  Photonics Lasers Med       Date:  2013-11-01

2.  Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus.

Authors:  Brian W Pogue; Chao Sheng; Juan Benevides; David Forcione; Bill Puricelli; Norm Nishioka; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

3.  Noninvasive measurement of aminolevulinic acid-induced protoporphyrin IX fluorescence allowing detection of murine glioma in vivo.

Authors:  Summer L Gibbs-Strauss; Julia A O'Hara; P Jack Hoopes; Tayyaba Hasan; Brian W Pogue
Journal:  J Biomed Opt       Date:  2009 Jan-Feb       Impact factor: 3.170

4.  In vivo photobleaching kinetics and epithelial biodistribution of hexylaminolevulinate-induced protoporphyrin IX in rat bladder cancer.

Authors:  Sami El Khatib
Journal:  Curr Urol       Date:  2021-03-29

5.  5-ALA Fluorescence in Native Pituitary Adenoma Cell Lines: Resection Control and Basis for Photodynamic Therapy (PDT)?

Authors:  Andrei Nemes; Thomas Fortmann; Stephan Poeschke; Burkhard Greve; Daniel Prevedello; Antonio Santacroce; Walter Stummer; Volker Senner; Christian Ewelt
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

6.  Photodynamic therapy dosimetry using multiexcitation multiemission wavelength: toward real-time prediction of treatment outcome.

Authors:  Monirehalsadat Mousavi; Lilian Tan Moriyama; Clovis Grecco; Marcelo Saito Nogueira; Katarina Svanberg; Cristina Kurachi; Stefan Andersson-Engels
Journal:  J Biomed Opt       Date:  2020-04       Impact factor: 3.170

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.